Featured Research

from universities, journals, and other organizations

Treatment for novel coronavirus shows promise in early lab tests

Date:
April 18, 2013
Source:
NIH/National Institute of Allergy and Infectious Diseases
Summary:
Scientists studying an emerging coronavirus have found that a combination of two licensed antiviral drugs, ribavirin and interferon-alpha 2b, can stop the virus from replicating in laboratory-grown cells. These results suggest that the drug combination could be used to treat patients infected with the new coronavirus, but more research is needed to confirm this preliminary finding.

Transmission electron micrograph of novel coronavirus.
Credit: NIAID/RML

National Institutes of Health (NIH) scientists studying an emerging coronavirus have found that a combination of two licensed antiviral drugs, ribavirin and interferon-alpha 2b, can stop the virus from replicating in laboratory-grown cells. These results suggest that the drug combination could be used to treat patients infected with the new coronavirus, but more research is needed to confirm this preliminary finding.

The study appears in the April 18, 2013, issue of Scientific Reports.

The new coronavirus, called nCoV, was first identified in Saudi Arabia in September 2012. As of April 16, 2013, the World Health Organization has reported 17 cases with 11 deaths, primarily in the Middle East. Although the case count is small, the new coronavirus has transmitted from human-to-human in situations where people -- mainly family members -- have had close contact with those infected.

Because of the high fatality rate, scientists at NIH's National Institute of Allergy and Infectious Diseases (NIAID) saw an urgent need to identify therapeutic options. In laboratory tests using cells from two species of monkey, the researchers found that either ribavirin or interferon-alpha 2b, drugs currently approved for hepatitis C therapy, inhibited nCoV from replicating when used individually. However, the required drug concentrations exceeded what is recommended for people. By combining the two antivirals, the scientists established an effective treatment dose at a drug level that is achievable in people. The NIAID researchers plan to confirm these results in a recently developed monkey model of nCoV infection.


Story Source:

The above story is based on materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


Journal References:

  1. Darryl Falzarano, Emmie de Wit, Cynthia Martellaro, Julie Callison, Vincent J. Munster, Heinz Feldmann. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Scientific Reports, 2013; 3 DOI: 10.1038/srep01686
  2. Vincent J. Munster, Emmie de Wit, Heinz Feldmann. Pneumonia from Human Coronavirus in a Macaque Model. New England Journal of Medicine, 2013; 368 (16): 1560 DOI: 10.1056/NEJMc1215691

Cite This Page:

NIH/National Institute of Allergy and Infectious Diseases. "Treatment for novel coronavirus shows promise in early lab tests." ScienceDaily. ScienceDaily, 18 April 2013. <www.sciencedaily.com/releases/2013/04/130418100115.htm>.
NIH/National Institute of Allergy and Infectious Diseases. (2013, April 18). Treatment for novel coronavirus shows promise in early lab tests. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/04/130418100115.htm
NIH/National Institute of Allergy and Infectious Diseases. "Treatment for novel coronavirus shows promise in early lab tests." ScienceDaily. www.sciencedaily.com/releases/2013/04/130418100115.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins